Sara Eichau

1.6k total citations
20 papers, 78 citations indexed

About

Sara Eichau is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Sara Eichau has authored 20 papers receiving a total of 78 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 6 papers in Neurology and 4 papers in Molecular Biology. Recurrent topics in Sara Eichau's work include Multiple Sclerosis Research Studies (15 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (4 papers). Sara Eichau is often cited by papers focused on Multiple Sclerosis Research Studies (15 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (4 papers). Sara Eichau collaborates with scholars based in Spain, Australia and Kuwait. Sara Eichau's co-authors include Fuencisla Matesanz, Guillermo Izquierdo, Helmut Butzkueven, Anneke van der Walt, Olga Skibina, Raed Alroughani, Manuel Vázquez-Marrufo, Alexey Boyко, Lívia Sousa and Pierre Grammond and has published in prestigious journals such as Journal of Neurology Neurosurgery & Psychiatry, Journal of Proteome Research and Multiple Sclerosis Journal.

In The Last Decade

Sara Eichau

17 papers receiving 77 citations

Peers

Sara Eichau
Pierre Grammond Australia
V. Di Tommaso Italy
Barnaby Fiddes United Kingdom
José Luis Sánchez-Menoyo Spain
Antonio Reia Italy
Melissa Ortega United States
N A Malkova Russia
Bonaventura Casanova Estruch Spain
Tai Wai Yeo Singapore
Michael Waltz United States
Pierre Grammond Australia
Sara Eichau
Citations per year, relative to Sara Eichau Sara Eichau (= 1×) peers Pierre Grammond

Countries citing papers authored by Sara Eichau

Since Specialization
Citations

This map shows the geographic impact of Sara Eichau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Eichau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Eichau more than expected).

Fields of papers citing papers by Sara Eichau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Eichau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Eichau. The network helps show where Sara Eichau may publish in the future.

Co-authorship network of co-authors of Sara Eichau

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Eichau. A scholar is included among the top collaborators of Sara Eichau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Eichau. Sara Eichau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Butzkueven, Helmut, Tomáš Kalinčík, Francesco Patti, et al.. (2024). Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders. 17. 4223502419–4223502419. 2 indexed citations
3.
Signori, Alessio, Marta Ponzano, Tomáš Kalinčík, et al.. (2024). Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. Journal of Neurology Neurosurgery & Psychiatry. 95(7). 620–625. 2 indexed citations
4.
Havrdová, Eva, Dana Horáková, Guillermo Izquierdo, et al.. (2024). No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry. Multiple Sclerosis Journal. 30(9). 1216–1220. 5 indexed citations
5.
Eichau, Sara, et al.. (2023). Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. Frontiers in Neurology. 14. 1112193–1112193. 5 indexed citations
6.
7.
8.
Walt, Anneke van der, Mastura Monif, Suzanne Hodgkinson, et al.. (2022). Prediction of relapse activity when switching to cladribine for multiple sclerosis. Multiple Sclerosis Journal. 29(1). 119–129. 3 indexed citations
9.
Eichau, Sara, et al.. (2022). Toxicidad sistémica secundaria a infiltración con anestésico local. Revista de Neurología. 75(5). 123–123.
10.
Malpas, Charles B., Izanne Roos, Sifat Sharmin, et al.. (2022). Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation. 42(4). 355–364. 9 indexed citations
11.
Jokubaitis, Vilija, Olga Skibina, Raed Alroughani, et al.. (2021). The MSBase pregnancy, neonatal outcomes, and women’s health registry. Therapeutic Advances in Neurological Disorders. 14. 4203290192–4203290192. 5 indexed citations
12.
Eichau, Sara, et al.. (2021). Deficits in Early Sensory and Cognitive Processing Are Related to Phase and Nonphase EEG Activity in Multiple Sclerosis Patients. Brain Sciences. 11(5). 629–629. 5 indexed citations
13.
14.
Eichau, Sara, et al.. (2020). Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports. Multiple Sclerosis and Related Disorders. 41. 102017–102017. 3 indexed citations
15.
Bass, Ann, Rafael Arroyo, Aaron Boster, et al.. (2020). Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders. 49. 102717–102717. 15 indexed citations
16.
17.
Eichau, Sara, et al.. (2019). Síndrome de Guillain-Barré tras infección por el virus de la hepatitis A. Medicina Clínica. 154(6). 238–239. 1 indexed citations
18.
Alroughani, Raed, Simon Broadley, Sara Eichau, et al.. (2018). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study). Multiple Sclerosis and Related Disorders. 26. 258–258. 1 indexed citations
19.
Eichau, Sara, et al.. (2018). Vitíligo con fenómeno de Koebner en una paciente con esclerosis múltiple tratada con alemtuzumab. Revista de Neurología. 66(11). 395–395. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre Grammond Breakdown of academic impact, for papers by V. Di Tommaso Breakdown of academic impact, for papers by Barnaby Fiddes Breakdown of academic impact, for papers by José Luis Sánchez-Menoyo Breakdown of academic impact, for papers by Antonio Reia Breakdown of academic impact, for papers by Melissa Ortega Breakdown of academic impact, for papers by N A Malkova Breakdown of academic impact, for papers by Bonaventura Casanova Estruch Breakdown of academic impact, for papers by Tai Wai Yeo Breakdown of academic impact, for papers by Michael Waltz
Rankless by CCL
2026